Issues related to CMMI drug pricing; 340B drug pricing
2026 · 2nd Quarter (Apr 1 - June 30)
MADRIGAL PHARMACEUTICALS, INC.
Filed by MADRIGAL PHARMACEUTICALS, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- Not reported
- Expenses
- $380,000.00
- Registrant
- MADRIGAL PHARMACEUTICALS, INC.
- Filing UUID
- ebbfb01d-ac42-4382-b9f1-84532f9ef444
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Most Favored Nation drug pricing; Issues related to CMMI drug pricing
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.